Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis c

Gastroenterology Nursing

Volumn 38, Issue 6, 2015, Pages 417-428

  LaFleur, Joanne ^a   Hoop, Robert ^b   Korner, Eli ^b   DuVall, Scott ^c   Morgan, Timothy ^d   Pandya, Prashant ^c   Han, Jian ^b   Knippenberg, Kristin ^a   Nelson, Richard E ^c  

^a Pharmacotherapy Outcomes Research Center   (United States)

^b GENENTECH INC   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

FEMALE; FORECASTING; HEPATITIS C, CHRONIC; HUMAN; MALE; MIDDLE AGED; UNITED STATES; VETERAN;

FEMALE; FORECASTING; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; UNITED STATES; VETERANS;

EID: 84952664329     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/SGA.0000000000000214     Document Type: Article

References (43)

1. Andriulli, A., Cursaro, C., Cozzolongo, R., Iacobellis, A., Valvano, M. R., Mangia, A., Andreone, P. (2009). Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin. Journal of Viral Hepatitis, 16 (1), 28-35.
2. Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006). The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine, 144 (10), 705-714.
3. Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., & Esteban, R. (2011). Boceprevir for previously treated chronic HCV Genotype 1 infection. The New England Journal of Medicine, 364 (13), 1207-1217.
4. Beste, L. A., Ioannou, G. N., Larson, M. S., Chapko, M., & Dominitz, J. A. (2010). Predictors of early treatment discontinuation among patients with Genotype 1 hepatitis C and implications for viral eradication. Clinical Gastroenterology and Hepatology, 8 (11), 972-978.
5. Brok, J., Gluud, L. L., & Gluud, C. (2010). Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews, (1), CD005445.
6. Brookhart, M. A., Patrick, A. R., Dormuth, C., Avorn, J., Shrank, W., Cadarette, S. M., & Solomon, D. H. (2007). Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect. American Journal of Epidemiology, 166 (3), 348-354.
7. Cacoub, P. (2008). Patient education improves adherence to peginterferon and ribavirin in chronic Genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study. World Journal of Gastroenterology, 14 (40), 6195-6203.
8. Carrion, J. A., Gonzalez-Colominas, E., Garcia-Retortillo, M., Canete, N., Cirera, I., Coll, S., Sola, R. (2013). A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. Journal of Hepatology, 59 (5), 926-933.
9. Centers for Disease Control and Prevention. (2004). Hepatitis surveillance report No. 59. Atlanta, GA: Author.
10. Centers for Disease Control and Prevention. (2012, August 16). Hepatitis C FAQs for health professionals. Retrieved March 13, 2013, from http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm.
11. Cheung, R. C., Currie, S., Shen, H., Ho, S. B., Bini, E. J., Anand, B. S., Wright, T. L. (2005). Chronic hepatitis C in Latinos: Natural history, treatment eligibility, acceptance, and outcomes. American Journal of Gastroenterology, 100 (10), 2186-2193.
12. Copegus [Prescribing information]. 2002). Nutley, NJ: Hoffman-La-Roche.
13. Dienstag, J. L., & McHutchison, J. G. (2006). American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology, 130 (1), 225-230.
14. Eslam, M., Aparcero, R., Mousa, Y. I., Grande, L., Shaker, Y., Ali, A., Romero-Gomez, M. (2012). Insulin resistance impairs viral dynamics independently of ethnicity or genotypes. Journal of Clinical Gastroenterology, 46 (3), 228-234.
15. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347 (13), 975-982.
16. Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011). An update on treatment of Genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54 (4), 1433-1444.
17. Hadziyannis, S. J., Sette, H., Jr. Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ackrill, A. M. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140 (5), 346-355.
18. Hussein, M., Benner, J. S., Lee, D., Sesti, A. M., Battleman, D. S., Brock-Wood, C. (2010). Propensity score matching in the evaluation of drug therapy management programs: An illustrative analysis of a program for patients with hepatitis C virus. Quality Management in Health Care, 19 (1), 25-33.
19. Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Zeuzem, S. (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine, 364 (25), 2405-2416.
20. Kwo, P. Y., Lawitz, E. J., McCone, J., Schiff, E. R., Vierling, J. M., Pound, D., Albrecht, J. K. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa- 2b and ribavirin in treatment-naive patients with Genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. The Lancet, 376 (9742), 705-716.
21. Ladero, J. M., Martin, E. G., Fernandez, C., Carballo, M., Devesa, M. J., Martinez, C., Agundez, J. A. (2012). Predicting response to therapy in chronic hepatitis C: An approach combining interleukin-28B gene polymorphisms and clinical data. Journal of Gastroenterology and Hepatology, 27 (2), 279-285.
22. Lafleur, J., Nelson, R. E., Sauer, B. C., & Nebeker, J. R. (2011). Overestimation of the effects of adherence on outcomes: A case study in healthy user bias and hypertension. Heart, 97 (22), 1862-1869.
23. Manns, M. P., Markova, A. A., Calle Serrano, B., & Cornberg, M. (2012). Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C Genotype 1. Liver International, 32 (Suppl. 1), 27-31.
24. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. The Lancet, 358 (9286), 958-965.
25. Marino, E. L., Alvarez-Rubio, L., Miro, S., Modamio, P., Banos, F., Lastra, C. F., & Alberdi-Leniz, A. (2009). Pharmacist intervention in treatment of patients with Genotype 1 chronic hepatitis C. Journal of Managed Care Pharmacy, 15 (2), 147-150.
26. McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., Albrecht, J. K. (2002). Adherence to combination therapy enhances sustained response in Genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123 (4), 1061-1069.
27. McHutchison, J. G., Manns, M. P., Muir, A. J., Terrault, N. A., Jacobson, I. M., Afdhal, N. H., Di Bisceglie, A. M. (2010). Telaprevir for previously treated chronic HCV infection. The New England Journal of Medicine, 362 (14), 1292-1303.
28. Murphy, R., Shvachko, V., & Manos, M. (2011, November 4-8). Patient perspectives about the treatment of hepatitis C (PATH-C). Paper presented at the American Association for the Study of Liver Diseases, San Francisco, CA.
29. Nunez, M., Ocampo, A., Aguirrebengoa, K., Cervantes, M., Pascual, A., Echeverria, S., Soriano, V. (2008). Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. Journal of Viral Hepatitis, 15 (5), 363-369.
30. Ogawa, E., Furusyo, N., Kajiwara, E., Takahashi, K., Nomura, H., Tanabe, Y., Hayashi, J. (2012). Evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha- 2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study. Journal of Gastroenterology and Hepatology, 27 (7), 1233-1240.
31. Poordad, F., McCone, J., Jr., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Bronowicki, J. P. (2011). Boceprevir for untreated chronic HCV Genotype 1 infection. The New England Journal of Medicine, 364 (13), 1195-1206.
32. Rebetol [Package insert]. (2006). Kenilworth, NJ: Schering Corporation.
33. Ribasphere [Package insert/prescribing information]. 2011 Warrendale, PA: Three Rivers Pharmaceuticals.
34. Saludes, V., Bracho, M. A., Valero, O., Ardevol, M., Planas, R., Gonzalez- Candelas, F., Martro, E. (2010). Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One, 5 (11), e14132.
35. Schmidt, C., Schulte, B., Hansefort, D., Goelz, J., Gerken, G., Scherbaum, N., Reimer, J. (2011, November 4-8). Optimizing HCV therapy: The impact of psychoeducation on retention and SVR in opiate substituted patients (Abstract). Paper presented at the American Association for the Study of Liver Diseases, San Francisco, CA.
36. Seal, K. H., Currie, S. L., Shen, H., Anand, B. S., Bini, E. J., Brau, N., Wright, T. L. (2007). Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: Does a history of injection drug use matter ? Journal of Clinical Gastroenterology, 41 (2), 199-205.
37. Sulkowski, M. S., Cooper, C., Hunyady, B., Jia, J., Ogurtsov, P., Peck- Radosavljevic, M., Dalgard, O. (2011). Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature Reviews. Gastroenterology & Hepatology, 8 (4), 212-223.
38. Tai, A. W., & Chung, R. T. (2009). Treatment failure in hepatitis C: Mechanisms of non-response. Journal of Hepatology, 50 (2), 412-420.
39. Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Dieterich, D. T. (2004). Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England Journal of Medicine, 351 (5), 438-450.
40. van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J. F., Lammert, F., Janssen, H. L. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308 (24), 2584-2593.
41. Weiss, J., Brau, N., Head, C., Marcus, S., Mindt, M. R., Stivala, A., & Dieterich, D. (2010). Early discontinuation of HCV treatment is not predicted by HIV status but by lifetime psychiatric diagnosis, poorer attention/psychomotor speed, and non-White race/ethnicity (Abstract no. MOPE0177). Paper presented at the AIDS 2010-XVIII International AIDS Conference, Vienna, Austria. Retrieved from https://www.aids2014.org/Default.aspx?pageId=12&abstractId=200740472v.
42. Yee, H. S., Chang, M. F., Pocha, C., Lim, J., Ross, D., Morgan, T. R., & Monto, A. (2012). Update on the management and treatment of hepatitis C virus infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. The American Journal of Gastroenterology, 107 (5), 669-689 ; quiz 690.
43. Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Beumont, M. (2011). Telaprevir for retreatment of HCV infection. The New England Journal of Medicine, 364 (25), 2417-2428.